-
Product Insights
New![]()
Trigeminal Neuralgia (Tic Douloureux) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Trigeminal Neuralgia (Tic Douloureux) Clinical Trials Overview The Trigeminal Neuralgia (Tic Douloureux) clinical trial report consists of 129 trials. The report provides an overview of the Trigeminal Neuralgia (Tic Douloureux) clinical trials scenario. The report provides top-line data relating to the clinical trials on Trigeminal Neuralgia (Tic Douloureux). It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 &...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Erenumab in Trigeminal Neuralgia (Tic Douloureux)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Erenumab in Trigeminal Neuralgia (Tic Douloureux) Drug Details: Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Basimglurant in Trigeminal Neuralgia (Tic Douloureux)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Basimglurant in Trigeminal Neuralgia (Tic Douloureux) Drug Details: Basimglurant (RG7090, RO4917523, R7090) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRAX-562 in Trigeminal Neuralgia (Tic Douloureux)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PRAX-562 in Trigeminal Neuralgia (Tic Douloureux)Drug Details:PRAX-562 is under development for the treatment of trigeminal neuralgia,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Trigeminal Neuralgia (Tic Douloureux)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Trigeminal Neuralgia (Tic Douloureux) Drug Details: ST-266 is under development for the treatment...
-
Product Insights
![]()
Uni of Strathclyde – TIC East and West Buildings – Glasgow City
Equip yourself with the essential tools needed to make informed and profitable decisions with our Uni of Strathclyde - TIC East and West Buildings - Glasgow City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Sector Analysis
![]()
Turkey Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast, 2023-2027
Turkey Construction Market Report Overview The Turkey construction market size was $103.9 billion in 2022. The market is projected to achieve an AAGR of more than 3% during 2024-2027. The market output in 2023 was supported by public and private sector investments in energy and residential building construction projects. The government is also making an effort to rebuild the housing and infrastructure that was damaged by the February 2023 earthquake. Market growth over the remainder of the forecast period will...
-
Product Insights
![]()
Wenshan TIC – Xilin-Guangnan Expressway – Guangxi Zhuang Autonomous Region
Equip yourself with the essential tools needed to make informed and profitable decisions with our Wenshan TIC - Xilin-Guangnan Expressway - Guangxi Zhuang Autonomous Region report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Optic Neuritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Optic Neuritis Drug Details: ST-266 is under development for the treatment of ocular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Chronic Traumatic Encephalopathy (CTE)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Chronic Traumatic Encephalopathy (CTE) Drug Details: ST-266 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Ocular Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-266 in Ocular Hypertension Drug Details:ST-266 is under development for the treatment of ocular hypertension, radiation-induced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Glaucoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ST-266 in Glaucoma Drug Details:ST-266 is under development for the treatment of ocular hypertension, radiation-induced dermatitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JBH-492 in B-Cell Non-Hodgkin Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JBH-492 in B-Cell Non-Hodgkin Lymphoma Drug Details: JBH-492 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Bladder Cancer Drug Details: HTL-0039732 is under development for the treatment of microsatellite...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GXG-3 in Chemotherapy Induced Neutropenia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GXG-3 in Chemotherapy Induced NeutropeniaDrug Details:GX-G3 (G-CSF-hyFc) is under development for the treatment of chemotherapy-induced neutropenia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TY-302 in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TY-302 in Prostate Cancer Drug Details:TY-302 Is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Oleclumab in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Oleclumab in Non-Small Cell Lung Cancer Drug Details: Oleclumab (MEDI-9447) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Myelofibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Myelofibrosis Drug Details: IMG-7289 is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alectinib in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Alectinib in Solid Tumor Drug Details:Alectinib (Alecensa / Alecensaro) is an antineoplastic agent. It is an...
-
Company Profile
![]()
Ferrero International SA – Company Profile
Ferrero International SA (Ferrero) is a holding company. It manufactures and markets chocolates and other confectionery products. The company's product portfolio comprises bakery products, snacks, pralines, mints and spreads. Ferrero markets its products under the brands Nutella, Kinder, Tic-Tac, Ferrero Rocher, Thorntons, Fannie May, Butterfinger and Eat Natural. Ferrero also offers semi-finished and finished hazelnut-based products. The company has business operations across Europe, the Americas, Asia, Oceania and Africa. Ferrero is headquartered in Senningerberg, Luxembourg.
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.